13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • D081SC00001 PROpel

    Acronym: 

    PROpel

    ACTRN/NCT /ethics: 

    NCT03732820

    Scientific title: 

    Study on Olaparib plus Abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer

    Summary of trial and patient characteristics

    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III Tumour Stream Prostate
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Male Anticipated Start Date 2018-10-31
    Molecular Target Anticipated End Date 2022-08-17
    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Male
    Molecular Target
    Tumour Stream Prostate
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date 2018-10-31
    Anticipated End Date 2022-08-17

    Trial Summary

    This is a phase III study evaluating the efficacy, safety, and tolerability of olaparib versus placebo when given in addition to abiraterone to genetically unselected patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting).

    Lay Summary

    Study on Olaparib plus Abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer

    Sponsor / Cooperative group

    AstraZeneca

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting